CVS Caremark says its new program that allows clients to exclude coverage of some drugs with high launch prices could potentially reshape how drugmakers behave.
According to The Hill, the PBM says the new program will utilize methods of analysis often seen in Europe, but not in America.
“No one but manufacturers have, until now, had any control over the launch price of newly patented drugs,” CVS said in a statement. “This new approach, harnessing the power of the market, could change manufacturer behavior.”
Drugs considered “breakthrough” therapies by the Food and Drug Administration will be excluded due to their high costs.
To read the full report on The Hill, click here.
